The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past
decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6 …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

The use of biological agents and immunomodulators for inflammatory bowel disease (IBD)
has remarkably improved disease management in the current era but at the same time has …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

Infliximab (IFX) has tremendously enriched the therapy of inflammatory bowel diseases
(IBD) and other immune mediated diseases. Although the efficacy of IFX was undoubtedly …

Background Elderly persons have the highest rates of tuberculosis (TB) in the United States
compared to all other age groups. A systematic literature review was conducted to determine …

Patients with inflammatory bowel disease (IBD) are at risk for hepatobiliary disease and
toxicity, and the diagnosis of drug-induced liver disease in patients being treated for IBD can …

Abstract Background and Aims: Despite having adopted preventive measures, tuberculosis
(TB) may still occur in patients with inflammatory bowel disease (IBD) treated with anti …

Aliment Pharmacol Ther 31, 553–560 Summary Background Most available data on
infliximab therapy come from large, short‐term, pivotal RCTs and concerns about long‐term …

Introduction: Latent tuberculosis infection is detected by the tuberculin skin test before
treating with anti-Tumour-Necrosis factor alpha (anti TNFα) reagents. More accurate are …